SCHEMBL3881940

SCHEMBL3881940

COc1ccc2cc(C(=O)Nc3ccc(CN)cc3)c(=O)oc2c1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.65
MAOA P21397 3/20 0.65
MAPT P10636 3/20 0.63
TP53 P04637 2/20 0.63
KLKB1 P03952 2/20 0.53
RXFP1 Q9HBX9 2/20 0.52
RAB9A P51151 1/20 0.50
PLG P00747 2/20 0.49
KLK1 P06870 2/20 0.49
KLK6 Q92876 2/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
PLEC Q15149 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882408 0.90 TP53 (0.63) MAOBMAOAMAPTTP53KLKB1
SCHEMBL4522469 0.88 TP53 (0.61) MAOBMAOAMAPTTP53KLKB1
SCHEMBL3882377 0.86 S1PR1 (0.59) MAOBMAOAMAPTTP53KLKB1
SCHEMBL3892055 0.86 TP53 (0.59) MAOBMAOAMAPTTP53KLKB1
SCHEMBL3880659 0.86 S1PR1 (0.65) MAOBMAOAMAPTTP53KLKB1
SCHEMBL3993825 0.86 TP53 (0.59) MAOBMAOAMAPTTP53KLKB1
SCHEMBL3878869 0.86 TP53 (0.59) MAOBMAOAMAPTTP53KLKB1
SCHEMBL4522651 0.85 MAOB (0.59) MAOBMAOAMAPTTP53RAB9A
SCHEMBL3882652 0.85 TP53 (0.58) MAOBMAOAMAPTTP53KLKB1
SCHEMBL4520278 0.84 CNR2 (0.62) MAOBMAOAMAPTTP53KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318546-A1 Chromen-2-One Derivatives NOVARTIS AG (CH) 2009-12-24 US claimed
EP-2010511-A1 CHROMEN-2-ONE DERIVATIVES Novartis AG (CH) 2009-01-07 EP claimed
WO-2007115820-A1 CHROMEN-2-ONE DERIVATIVES NOVARTIS AG (CH) 2007-10-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318546-A1 Chromen-2-One Derivatives CYP1A2, CYP4B1, CYP1B1 MAOB 1375/4885MAOA 1782/4885MAPT 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.